Niagen Bioscience

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NAGE and other ETFs, options, and stocks.

About NAGE

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). 

CEO
Robert N. Fried
CEORobert N. Fried
Employees
117
Employees117
Headquarters
Los Angeles, California
HeadquartersLos Angeles, California
Founded
1999
Founded1999
Employees
117
Employees117

NAGE Key Statistics

Market cap
408.41M
Market cap408.41M
Price-Earnings ratio
24.88
Price-Earnings ratio24.88
Dividend yield
Dividend yield
Average volume
2.36M
Average volume2.36M
High today
$5.28
High today$5.28
Low today
$4.80
Low today$4.80
Open price
$4.93
Open price$4.93
Volume
2.79M
Volume2.79M
52 Week high
$14.69
52 Week high$14.69
52 Week low
$4.73
52 Week low$4.73

Stock Snapshot

The current Niagen Bioscience(NAGE) stock price is $5.09, with a market capitalization of 408.41M. The stock trades at a price-to-earnings (P/E) ratio of 24.88.

As of 2026-03-09, Niagen Bioscience(NAGE) stock has fluctuated between $4.80 and $5.28. The current price stands at $5.09, placing the stock +6.0% above today's low and -3.6% off the high.

Niagen Bioscience(NAGE) shares are trading with a volume of 2.79M, against a daily average of 2.36M.

In the last year, Niagen Bioscience(NAGE) shares hit a 52-week high of $14.69 and a 52-week low of $4.73.

In the last year, Niagen Bioscience(NAGE) shares hit a 52-week high of $14.69 and a 52-week low of $4.73.

NAGE News

TipRanks 23h
ChromaDex Earnings Call: Strong Growth, Cautious Outlook

ChromaDex Corporation ((NAGE)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 70% Off TipRanks Premium Unlock hedge fund-leve...

Simply Wall St 2d
The Bull Case For Niagen Bioscience Could Change Following Record 2025 Results And Injectable Expansion

Niagen Bioscience recently reported its strongest year to date, with 2025 net sales reaching US$129.4 million, net income of US$17.4 million, and management gui...

The Bull Case For Niagen Bioscience Could Change Following Record 2025 Results And Injectable Expansion
Simply Wall St 4d
Niagen Bioscience Valuation Check After Strong 2025 Results And Moderated 2026 Growth Outlook

Niagen Bioscience (NAGE) is back in focus after reporting strong 2025 revenue and profit growth that exceeded its own guidance, while also laying out moderated...

Niagen Bioscience Valuation Check After Strong 2025 Results And Moderated 2026 Growth Outlook

Analyst ratings

100%

of 6 ratings
Buy
100%
Hold
0%
Sell
0%

More NAGE News

TipRanks 4d
Niagen Bioscience price target lowered to $13 from $14 at Canaccord

Canaccord analyst Susan Anderson lowered the firm’s price target on Niagen Bioscience (NAGE) to $13 from $14 and keeps a Buy rating on the shares. The firm upda...

Benzinga 5d
Niagen Bioscience Rallies 18% After Hours: Here's Why

Niagen Bioscience Inc. (NASDAQ:NAGE) jumped 18.41% in after-hours trading on Wednesday to $5.85. Shares of the Los Angeles-based biotechnology company closed t...

Niagen Bioscience Rallies 18% After Hours: Here's Why
Seeking Alpha 5d
Niagen Bioscience targets 10–15% revenue growth for 2026 while expanding injectable product line

Earnings Call Insights Niagen Bioscience targets 10–15% revenue growth for 2026 while expanding injectable product line Mar. 04, 2026 7:12 PM ET Niagen Bioscien...

Niagen Bioscience targets 10–15% revenue growth for 2026 while expanding injectable product line
TipRanks 5d
Niagen Bioscience Reports Strong 2025 Results, Strategic Shift

Niagen Bioscience ( (NAGE) ) just unveiled an update. Niagen Bioscience reported on March 4, 2026 that 2025 net sales rose 30% year over year to $129.4 million...

Benzinga 5d
Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion

Niagen Bioscience (NASDAQ:NAGE) , whose anti-aging product counts longevity entrepreneur Bryan Johnson among its customers, reported its strongest financial res...

Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion

People also own

Based on the portfolios of people who own NAGE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.